Crescent Biopharma (CBIO) Other Operating Expenses (2024 - 2026)
Crescent Biopharma (CBIO) posted quarterly Other Operating Expenses of $1.8 million for Q2 2026, down 89.48% quarter-over-quarter from $16.8 million in Q4 2025.
Crescent Biopharma (CBIO) Other Operating Expenses (2024 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Other Operating Expenses for 3 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Operating Expenses changed N/A year-over-year to $1.8 million; the TTM figure through Jun 2026 stood at $18.6 million (up 1418.19% YoY), while the FY2024 annual figure was $1.2 million, changed N/A from the prior year.
- Other Operating Expenses fell to $1.8 million in Q2 2026 per CBIO's latest filing, from $16.8 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $16.8 million in Q4 2025 and bottomed at $1.2 million in Q3 2024.
- Historically, Other Operating Expenses has averaged $6.6 million across 3 years, with a median of $1.8 million in 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.77 Mn |
| Dec 31, 2025 | 16.83 Mn |
| Sep 30, 2024 | 1.22 Mn |